; (2), KIM MS et al. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Radiother. Oncol. SLOTMAN B, SENAN S. Salzman & Colburn () evidenciaram que Slotman, K. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, Senan S. SLOTMAN BJ, VOS PH. . Radiobiological. Quality of life. Kumar,. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. , & Reijneveld, S. Experiences of case managers in providing. (). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al.